Search

Fresenius is expanding its biosimilar business through a partnership with the Chinese manufacturer WuXi Biologics, which includes up to 37 new products, with the first biosimilars expected to hit the market in the early 2030s. #Biosimilars #Fresenius #WuXiBiologics (translated)

www.derstandard.at

Fresenius baut Biosimilar-Geschäft mit chinesischem Partner WuXi aus